2 weeks after I started that product I added one more product for my breathing and the Doctor told me to nebulize it 4 times a day. The results were felt almost immediately. I was astonished at how fresh the air felt once again (like when I was 21 lol) I also joined this company as it is free to join through December 30 ( and I also get a discount). It is also a precursor to glutathione. This product is a miracle for me. I no longer require rescue inhalers every 6 hrs., no steroids or steroid inhalers! If I have to use my rescue it’s 1/2 dose watered down with hypotonic sea water, and now, most days, I don’t even need it. I can exercise. I am breathing at night, sleeping, no anxiety and this is honestly what helped me the quickest! This helped me more than any natural product I have ever tried in my life. I also wanted Inhaled Glutathione which is available at http:// and other compounding pharmacies. My naturopath told me that she used it for asthma and it didn’t work for her. It works wonders for some however. I now believe that a precursor to stimulate the glutathione in my own body is most effective. You can purchase glutathione but it doesn’t as your body will simply digest it and it will be eliminated. Too many studies have been done on the subject. I even took NAC supplements but they didn’t work at all. Here is the site for the spray, please read the testimonials. I hope it’s ok to put the web site on here. If not, please excuse me. I just want everyone with this horrible illnes to get free from the devastating side effects of feeling like your suffocating all the time. Here it is: http:///balance
Great question! Unfortunately, there are side effects to taking steroids – inhaled or oral. However, the risk of suppressing the immune system with inhaled corticosteroids is far less than with the use of systemic steroids.
For a person with asthma, inhaled steroids are an important part of treatment. They reduce the airway inflammation that is the hallmark of asthma. So, when prescribing inhaled steroids most doctors weigh carefully the benefits vs. the risks. Most likely you’re on the lowest possible dose for the severity of your asthma – enough to treat the inflammation and avoid exacerbations. One of the benefits of inhaled steroids is that they are being delivered directly to the area needed, which is one of the reasons a much lower dosing can be used with far less side effects. In fact, it takes about a year of inhaled steroids to equal a 5 day course of oral steroids prescribed during an exacerbation .
There has been recent uncertainty about whether the inhaled anticholinergic agents ipratropium bromide and tiotropium bromide increase or decrease cardiovascular risk in the treatment of patients with chronic obstructive pulmonary disease (COPD). This article synthesizes the available data in order to understand the controversy. COPD is a common cause of hospitalizations and is a rapidly increasing cause of mortality worldwide. Despite the heavy burden of COPD-related illness, the leading cause of hospitalization in COPD patients is cardiovascular disease. This link between COPD and cardiovascular disease is in part due to the fact that both diseases share common risk factors, such as tobacco smoking and advanced age. It is also hypothesized that systemic inflammation in COPD increases the risk for cardiac events such as myocardial infarction. Inhaled anticholinergics reduce COPD-related hospitalizations and respiratory deaths compared with placebo, and tiotropium bromide is more effective than ipratropium bromide. In randomized trials, patients receiving tiotropium bromide have lower discontinuation rates than those receiving placebo and, therefore, contribute more person-years to the analyses. In a recent large 4-year tiotropium bromide trial, the proportion of patients who died was similar in the tiotropium bromide and placebo groups, whereas the death rate per person-years was lower with tiotropium bromide, indicating longer overall survival. There has been conflicting evidence concerning cardiovascular risk associated with inhaled anticholinergics. One meta-analysis found that the risk for major cardiovascular events was higher with anticholinergics compared with placebo or active comparator controls, whereas two subsequent meta-analyses that included new trial data found no difference in risk. In a recent pooled safety analysis, when incidence rates of events over time were evaluated, tiotropium bromide was associated with a lower rate of major cardiovascular events and cardiovascular deaths compared with placebo. This risk reduction was mainly because of a reduction in serious cardiac events such as myocardial infarction and congestive heart failure. In conclusion, inhaled anticholinergics, especially tiotropium bromide, reduce COPD-related hospitalizations and deaths, and may improve total survival over time. Many COPD patients have concomitant cardiovascular disease processes. Thus, trials may observe more cardiovascular events associated with anticholinergics than with placebo, but this differential is eliminated when evaluating the rate of events per person-years of exposure. New evidence indicates that tiotropium bromide may actually reduce the incidence of cardiovascular events and deaths over time. It is possible that the reduction in respiratory morbidity could improve functional status and reduce adverse cardiac outcomes over time. Further studies are needed to address this important issue.